Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

Patients with primarily moderate to severe hypercortisolism were randomized to receive pasireotide sc injection in doses of 900 micrograms (n=80) or 600 micrograms (n=82) twice daily. The primary endpoint was the proportion of patients who achieved normalization of UFC after six months without dose up-titration relative to randomized dose. The primary endpoint was met in patients treated with 900 microgram sc twice daily. Secondary endpoints included safety, proportion of patients with UFC </= ULN at months 3, 6 and 12 regardless of dose titration, proportion of patients with partial UFC control (defined as UFC > ULN and >/= 50% reduction from baseline); changes from baseline in plasma adrenocorticotropic hormone (ACTH), UFC, serum and salivary cortisol over time and changes from baseline in clinical signs, symptoms and health-related quality of life(1).

After six months, the primary efficacy responder rate was 26.3% (95% confidence interval [CI], 16.6 to 35.9) and 14.6% (95% CI, 7.0 to 22.3), respectively, for the 900 microgram and 600 microgram groups. Based on pre-specified criteria (lower bound of 95% CI >15%), the 900 microgram group met the primary endpoint and the 600 microgram group did not meet the primary endpoint. After 12 months, the proportion of responders regardless of dose up-titration was 25.0% and 13.4%, respectively, for the 900 microgram and 600 microgram groups. The median reduction in UFC after six months was 47.9% for both groups. The median reduction in UFC after 12 months was 62.4% (900 microgram) and 67.6% (600 microgram). In patients with full or partial control of UFC levels at months 1 or 2, 71.4% remained on treatment until month 12 compared with 24.6% of those uncontrolled at months 1 and 2(1).

Adverse events associated with cortisol levels below the normal range were experienced by 13 patients. This was managed by dose reduction without loss of efficacy. There were no deaths during pasireotide treatme
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Patterson Medical, formerly the medical business ... is now an independent company with today,s completion ... by Madison Dearborn Partners (MDP).  ... transition period before rebranding as the world,s leading ...  With the focused resources and expertise of MDP, ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ... Report on China,s Ranibizumab Market, 2012-2019" report to ... approved by CFDA to treat wet age- related macular ... of Novartis, is available in the Chinese market. However, ... for the treatment of wet AMD in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... MESA, Ariz., March 16, 2012 /PRNewswire/ -- On ... filed a collective action lawsuit against Sunovion Pharmaceuticals for failure ... are entitled under the Fair Labor Standards Act (FLSA). The Complaint ... District of Oregon on behalf of all Sunovion pharmaceutical reps ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with inflammation and autoimmune disorders, today provided an update ... VISTA-16 clinical study. Immediately after the ... clinical study, the Company took steps to cease patient ...
Cached Medicine Technology:JacksonWhite Files Overtime Lawsuit Against Sunovion Pharmaceuticals 2Anthera Provides Corporate Update on Recent Activities 2
(Date:8/28/2015)... ... 28, 2015 , ... For Dallas, the time is nearing for the annual ... Tenet Health. , The American Heart Association hosts their well-known Heart Walk to raise ... together, a difference can be made. Walkers can participate in the cause and someone ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... As ... from Merz, received FDA clearance for results that last for two years, the ... exciting news for patients who are looking for a long-lasting, effective solution for their ...
(Date:8/28/2015)... , ... August 28, 2015 , ... On May 30th, ... joined as sponsor of the “Music With A Mission” benefit concert in Mendon, IL. ... event was to raise money to support music education programs in the underfunded local ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL ... with zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 ... 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products ...
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, Inc., the ... and data center assets and audio-video devices, recently released Visio Stencils for the ... HP ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... , , BOTHELL, Wash., Sept. ... ) announced today that on September 15, 2009, the NYSE ... with respect to its previously disclosed listing deficiency as set ... Such deficiency relates to the Company,s failure to maintain stockholder,s ...
... SOMERSET, N.J., Sept. 18 TeamStaff, Inc. ... healthcare and administrative staffing services, today announced that on September ... Department of The Nasdaq Global Market (Nasdaq) stating that for ... has not maintained a minimum market value of publicly held ...
... , CHICAGO, Sept. 18 As economic, ... in Illinois, the state,s leading provider of addiction treatment services ... people who can,t afford expensive clinics but also fail to ... Gateway Foundation Inc., a 41-year-old non-profit organization, serves more than ...
... stems from access to alcohol or feelings of isolation remains ... study suggests there,s a link between suicide and rural communities ... research doesn,t confirm that more bars mean more suicides because ... those who commit suicide, about 20 percent are alcoholics, according ...
... SAN FRANCISCO, Sept. 18 VIA Pharmaceuticals, Inc. ... the development of compounds for the treatment of cardiovascular and ... received a deficiency letter from the NASDAQ Stock Market stating ... $1.00 per share bid price requirement for continued listing, as ...
... , , BROOMFIELD, Colo., Sept. 18 Accera, ... diseases, today announced today that it will present at the UBS ... , , Steve Orndorff, Ph.D., founder, president and ... on Axona (TM) on Monday, September 21 at 11:30 a.m. ...
Cached Medicine News:Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Health News:TeamStaff Receives Nasdaq Deficiency Notice Related to the Market Value of Its Publicly Held Shares 2Health News:TeamStaff Receives Nasdaq Deficiency Notice Related to the Market Value of Its Publicly Held Shares 3Health News:Gateway Responding To Increased Need for Treatment Among Middle-Income Substance Abusers 2Health News:Suicides Higher in Rural Areas With Bars 2Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 2Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 3Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 4Health News:Accera, Inc. to Present at UBS Global Life Sciences Conference 2
Inquire...
Inquire...
Inquire...
... Optimal for Subcellular Fractionation, Proteins ... g (30,000 rpm) with fixed-angle ... 0.25 up to 85 mL ... C to 40° C • ...
Medicine Products: